智通财经APP讯，复星医药(02196)公布，该集团于 2022 年 1 月参与发起设立苏州天使基金，截至本公告日期，该基金已获认缴人民币1.76亿元(已获实缴人民币 9425 万元);其中，该集团(通过控股子公司宁波复瀛)认缴人民币1.1亿元(已实缴人民币 6125 万元)、星盛复盈认缴人民币 300 万元(已实缴人民币 150 万元)、苏州天使母基金认缴人民币 6300 万元(已实缴人民币 3150 万元)，分别持有该基金 62.50%、1.70%、35.80%的份额。
鉴于该基金投资期即将届满并考虑届满前投资计划之资金需求，经各方协商，全体合伙人同意对苏州天使基金进行同比例减资，减资总额为人民币 7600 万元。本次减资完成后，苏州天使基金财产份额将由人民币1.76亿元减少至1亿元，其中星盛复盈、宁波复瀛、苏州天使母基金认缴出资额分别减少人民币 129.5455 万元、4,750.0000 万元、2,720.4545 万元。本次减资前后，全体合伙人持有的苏州天使基金财产份额比例不变。
由于本次减资所涉及的苏州天使基金份额已获认缴但尚未获实缴，因此，苏州天使基金无需就本次减资向各减资方支付对价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.